iiinova — where your digital self keeps evolving

Timothy Voorhees, MD, MSCR

@tvoorheesmd.bsky.social

Assistant Professor @OSUCCC_James | #Lymphoma | Previously @UNC_Lineberger & @OSUWexMed | Proud Dad/Husband | Tweets & Opinions Are My Own, Not Medical Advice

Posts Replies Media

Reposted by Timothy Voorhees, MD, MSCR

Ohio State Hematology @osuhematology.bsky.social · 08/04/2025

Timothy Voorhees, MD @tvoorheesmd.bsky.social published "Outcomes in patients with classic #Hodgkinlymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers" in @BloodCancerJnl. 🔗https://pubmed.ncbi.nlm.nih.gov/40140364/

011

Timothy Voorhees, MD, MSCR @tvoorheesmd.bsky.social · 19/11/2024

Important data for CD20 bispecific therapy - no significant effect of prior bendamustine exposure.

021